Tech Company Financing Transactions
Cerulean Pharma Funding Round
Polaris Partners, Lux Capital and Venrock participated in a $12.1 million Series A funding round for Cerulean Pharma. This venture round closed on 5/23/2007.
Transaction Overview
Company Name
Announced On
5/23/2007
Transaction Type
Venture Equity
Amount
$12,100,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the financing will be used to accelerate the development of Tempo's preclinical pipeline of multi-compartmental, nanoparticle-based drugs that have the potential to substantially improve the efficacy and safety of existing and new therapeutics.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
840 Memorial Dr.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Cerulean Pharma develops nanotechnology-based therapeutics for treating oncology, cardiovascular, autoimmune and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Friedman
VP - Bus. Development
Christopher Guiffre
VP - Finance
Karen Roberts
VP - Manufacturing
Marc Wolfgang
VP - R & D
Scott Eliasof
Browse more venture capital transactions:
Prev: 5/22/2007: QuatRx Pharmaceuticals venture capital transaction
Next: 5/23/2007: Greystripe venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs